Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alseres Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Bobby Berry who wrote (604)	11/5/1998 2:25:00 PM
From: john e vanden biesen	Read Replies (1) \| Respond to of 975

Good news on patent protection for Toponin:protection granted for solid tumors,retinalneovascularization,coronary athlerosclerosis, spinal injury.Should hear soon about therafectin NDA in 3 or 4 weeks? Corporate partner should be forthcoming due to patent protection. By end of year?Troponin NDA early 99. Solid tumor and opthalmic indications proven in animal models. Solid tumor and opthalmic indications each have billion dollar potential.I am LONG 4k shrs BLSI. JOHNV.